Press release
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® moleculesCompanies to leverage Immatics' XPRESIDENT®
About this update from Moderna, Inc.
[{"type":"text","content":"Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® moleculesCompanies to leverage Immatics' XPRESIDENT® target discovery platform and Moderna's mRNA technology for the development of novel cancer vaccinesCollaboration to include evaluation of Immatics' investigational IMA203 PRAME TCR-T in combination with Moderna's investigational PRAME mRNA cancer vaccineImmatics to receive $120 million upfront cash payment plus research funding with the potential for additional milestone and royalty paymentsCAMBRIDGE, MA and TUEBINGEN, GERMANY / ACCESSWIRE / September 11, 2023 / Moderna, Inc. (NASDAQ:MRNA, \"Moderna\") and Immatics N.V. (NASDAQ:IMTX, \"Immatics\"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need. This broad multi-platform collaboration will leverage the deep scientific expertise and core operational capabilities of both companies, combining Immatics' TCR platform with Moderna's cutting-edge mRNA technology, and span various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.The strategic R&D collaboration between Moderna and Immatics focuses on three pillars:Applying Moderna's mRNA technology for in vivo expression of Immatics' next-generation, half-life extended TCR bispecifics (TCER®) targeting cancer-specific HLA-presented peptides.Enabling the discovery and development of novel mRNA-based cancer vaccines by leveraging Moderna's deep knowledge of mRNA science and customized information from Immatics' wealth of tumor and normal tissue data included in the target discovery platform XPRESIDENT® and its bioinformatics and AI platform XCUBE™.Evaluating Immatics' IMA203 TCR-T therapy targeting PRAME in combination with Moderna's PRAME mRNA-based cancer vaccine. The collaboration contemplates conducting preclinical studies and a Phase 1 clinical trial evaluating the safety and efficacy of the combination with the objective of further enhancing IMA203 T cell responses.\"We are excited to embark on this strategic collaboration with Immatics, a pioneer in developing innovative cancer immunotherapies. This partner...